ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2707

Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome

Nilasha Ghosh1, Xuan Cai2 and Cybele Ghossein3, 1Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: outcomes, renal disease and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function. Historically, development of SRC was almost always fatal. With the use of angiotensin-converting enzyme inhibitors (ACEI), one-year survival has improved up to 76%; however, SRC remains a poor prognostic marker for long-term survival. Dialysis dependency after an episode of SRC portends a worse long-term prognosis. Here we report on our 15 years of experience with SRC at our institution with a focus on identifying characteristics that predicted initiation of dialysis or death.

Methods: We undertook a retrospective single-center chart review of patients aged 18-80 years old that developed SRC between the years 2002-2016. Baseline characteristics such as age, gender, race, comorbidities and exposures were noted. Outcome data was collected at time of admission, 6 months and 12 months. Patients with the diagnosis of scleroderma and acute kidney injury for any other reason other than SRC were excluded.

Results: In the 15-year period, we identified 34 patients with an episode of SRC (table 1). Of these patients, 16 developed poor outcome (death or dialysis) during their hospital admission. Exposure to steroids within one month of admission was similar in both groups; however, poor outcome was more common in those with exposure to ≥40mg prednisone (p=0.007). This trend continued at the 6 and 12-month follow-up.

Conclusion: Exposure to steroids is known to be a risk factor for the development of SRC. Use of higher dosages of steroids may also be associated with worse outcomes in patients with SRC.

Table 1. Results are reported as proportions or means ± standard deviation or ranges

Death or Dialysis

(n=16)

Recovered

(n=18)

p-value

Age, mean ± SD, years

47.7 ± 14.6

53.9 ± 12.5

0.19

Female, n%

11 (68.8)

17 (94.4)

0.05

Systolic blood pressure, mmHg

161.7 ± 46.4

161.7 ± 46.4

0.05

Diastolic blood pressure, mmHg

89.0 ± 20.5

99.9 ± 21.7

0.14

Duration of disease, years

0.6-2.3

0.5-2.0

0.37

RNA Polymerase III +

10 (71.4)

11 (64.7)

0.69

ACEI exposure

10 (62.5)

10 (55.6)

0.68

Steroid exposure

10 (62.5)

12 (66.7)

0.80

Dose of prednisone, mg

40.0-1000.0

5.0-30.0

0.007

Thrombotic Microangiopathy (TMA)

7 (58.3)

3 (37.5)

0.36

Related to stem-cell transplant

5 (31.3)

1 (5.6)

0.05


Disclosure: N. Ghosh, None; X. Cai, None; C. Ghossein, None.

To cite this abstract in AMA style:

Ghosh N, Cai X, Ghossein C. Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/scleroderma-renal-crisis-the-association-of-high-dose-steroids-and-poor-outcome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/scleroderma-renal-crisis-the-association-of-high-dose-steroids-and-poor-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology